EP2922827A4 - METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE - Google Patents
METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASEInfo
- Publication number
- EP2922827A4 EP2922827A4 EP13857254.0A EP13857254A EP2922827A4 EP 2922827 A4 EP2922827 A4 EP 2922827A4 EP 13857254 A EP13857254 A EP 13857254A EP 2922827 A4 EP2922827 A4 EP 2922827A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- bruton
- disease
- treating
- methods
- tyrosine kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728701P | 2012-11-20 | 2012-11-20 | |
US201361870720P | 2013-08-27 | 2013-08-27 | |
PCT/US2013/070772 WO2014081712A2 (en) | 2012-11-20 | 2013-11-19 | Methods of treating a disease or disorder associated with bruton's tyrosine kinase |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2922827A2 EP2922827A2 (en) | 2015-09-30 |
EP2922827A4 true EP2922827A4 (en) | 2016-06-08 |
Family
ID=50776662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13857254.0A Withdrawn EP2922827A4 (en) | 2012-11-20 | 2013-11-19 | METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2922827A4 (zh) |
TW (1) | TW201427667A (zh) |
WO (1) | WO2014081712A2 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2578585B1 (en) | 2010-05-31 | 2016-07-20 | ONO Pharmaceutical Co., Ltd. | Purinone derivative as btk kinase inhibitor |
DK2786996T3 (en) | 2011-11-29 | 2016-12-19 | Ono Pharmaceutical Co | Hydrochloride PURINONDERIVAT |
CN105188371A (zh) | 2013-02-08 | 2015-12-23 | 西建阿维拉米斯研究公司 | Erk抑制剂及其用途 |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
EP3066126B1 (en) * | 2013-11-07 | 2019-03-27 | F. Hoffmann-La Roche AG | Combination therapy of an anti cd20 antibody with a btk inhibitor |
ES2806506T3 (es) | 2014-03-25 | 2021-02-17 | Ono Pharmaceutical Co | Agente profiláctico y/o agente terapéutico para el linfoma difuso de células B grandes |
US10005760B2 (en) | 2014-08-13 | 2018-06-26 | Celgene Car Llc | Forms and compositions of an ERK inhibitor |
US10239879B2 (en) | 2015-04-09 | 2019-03-26 | Ono Pharmaceutical Co., Ltd. | Process for producing purinone derivative |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011153514A2 (en) * | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2013063401A1 (en) * | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1616572T3 (da) * | 1998-11-09 | 2010-12-06 | Biogen Idec Inc | Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi |
US8338439B2 (en) * | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CA2807051A1 (en) * | 2010-08-10 | 2012-02-16 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
CN102093421B (zh) * | 2011-01-28 | 2014-07-02 | 北京康辰药业有限公司 | 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
EP2694486B1 (en) * | 2011-04-01 | 2018-01-10 | University of Utah Research Foundation | Substituted n-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase btk inhibitors |
-
2013
- 2013-11-19 EP EP13857254.0A patent/EP2922827A4/en not_active Withdrawn
- 2013-11-19 TW TW102142189A patent/TW201427667A/zh unknown
- 2013-11-19 WO PCT/US2013/070772 patent/WO2014081712A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011153514A2 (en) * | 2010-06-03 | 2011-12-08 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
WO2013063401A1 (en) * | 2011-10-28 | 2013-05-02 | Celgene Avilomics Research, Inc. | Methods of treating a bruton's tyrosine kinase disease or disorder |
Non-Patent Citations (2)
Title |
---|
JAN A BURGER ET AL: "The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients", 1 November 2012 (2012-11-01), pages 187, XP002736107, ISSN: 0006-4971, Retrieved from the Internet <URL:https://ash.confex.com/ash/2012/webprogram/Paper47509.html> * |
RAJENDRA N DAMLE ET AL: "Changes in immune cell populations in relapsed/refractory CLL patients treated with a Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in combination with Bendamustine and Rituximab (BR)", 15 April 2013 (2013-04-15), pages 3531, XP002736105, ISSN: 1538-7445, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/73/8_Supplement/3531.short> DOI: 10.1158/1538-7445.AM2013-3531 * |
Also Published As
Publication number | Publication date |
---|---|
TW201427667A (zh) | 2014-07-16 |
EP2922827A2 (en) | 2015-09-30 |
WO2014081712A3 (en) | 2015-07-16 |
WO2014081712A2 (en) | 2014-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2770830A4 (en) | METHODS OF TREATING A DISEASE OR DISEASE ASSOCIATED WITH TYROSINE KINASE BTK (BRUTON'S TYROSINE KINASE) | |
IL238571A0 (en) | Broton tyrosine kinase inhibitors, preparations containing them and their uses | |
IL269511A (en) | New therapeutic approaches to treat Parkinson's disease | |
IL266648B (en) | A method for treating Parkinson's disease | |
EP2922827A4 (en) | METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE | |
EP2925740A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
IL245042A0 (en) | Treatment with proton tyrosine kinase inhibitors and immunotherapy | |
EP2809673A4 (en) | CYCLIC MOLECULES AS AN INHIBITORS OF BRUTON TYROSINE KINASE | |
SG11201602421VA (en) | Inhibitors of bruton's tyrosine kinase | |
EP2858500A4 (en) | INHIBITORS OF BRUTON TYROSINE KINASE | |
EP2922546A4 (en) | METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE | |
ZA201400012B (en) | Inhibitors of bruton's tyrosine kinase | |
ZA201308397B (en) | Inhibitors of bruton's tyrosine kinase | |
EP2844256A4 (en) | TREATMENT OF NEURAL DISEASE WITH TYROSINE KINASE INHIBITORS | |
ZA201400739B (en) | Inhibitors of bruton's tyrosine kinase | |
EP2911664A4 (en) | COMBINATION THERAPIES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES | |
EP2833886A4 (en) | SUBSTITUTED QUINOLINES AS INHIBITORS OF BRUTON TYROSINE KINASES | |
HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
EP2680842A4 (en) | METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM | |
IL231757A0 (en) | Treatment of malignant and nonmalignant diseases with ras antagonists | |
EP2922826A4 (en) | METHOD FOR THE TREATMENT OF A DISEASE OR DISEASE RELATED TO BRUTON TYROSINE KINASE | |
ES2627541T8 (es) | Métodos para tratar la enfermedad de Parkinson | |
EP2814474A4 (en) | METHOD FOR THE TREATMENT AND PREVENTION OF DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM | |
EP2906225A4 (en) | METHODS OF TREATING KENNEDY'S DISEASE | |
EP2892538A4 (en) | METHOD FOR TREATING BRUTON TYROSINE KINASE ILLNESS OR DISORDER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150615 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20160511 |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20171114 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20180327 |